Frankfurt - Delayed Quote EUR

Merus N.V. (2GH.F)

41.00

+2.80

(+7.33%)

At close: April 26 at 3:29 PM GMT+2

Key Events

Advanced Chart

Loading Chart for 2GH.F

9/21 12:03 PM

DELL

Previous Close 38.20
Open 41.20
Bid 41.80 x --
Ask 43.20 x --
Day's Range 41.00 - 41.20
52 Week Range 16.40 - 48.60
Volume 20
Avg. Volume 32
Market Cap (intraday) 2.464B
Beta (5Y Monthly) 1.11
PE Ratio (TTM) --
EPS (TTM) -2.80
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 30.71

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

www.merus.nl

172